This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of -33.33% and 24.31%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
by Zacks Equity Research
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
by Zacks Equity Research
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
by Zacks Equity Research
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
by Zacks Equity Research
Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
by Zacks Equity Research
Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.
Here's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Aridis Pharmaceuticals (ARDS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 17.78% and 4.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study
by Zacks Equity Research
DICE Therapeutics (DICE) reports positive top-line data from a phase I study, evaluating its lead candidate DC-806 for treating psoriasis. Stock up.
Albireo (ALBO) Up on Results From Alagille Syndrome Study
by Zacks Equity Research
Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.
scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval
by Zacks Equity Research
scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
by Zacks Equity Research
Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.
Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study
by Zacks Equity Research
Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size
by Zacks Equity Research
Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.
9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate
by Zacks Equity Research
9 Meters (NMTR) reports a positive top line from a phase II study of vurolenatide, being evaluated for short bowel syndrome in adults and a successful end-of-phase II meeting with the FDA.
DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold
by Zacks Equity Research
DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.
Wave Therapeutics (WVE) Up on Update From Huntington's Study
by Zacks Equity Research
Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.
Intellia (NTLA) Reports Positive Results for CRISPR Candidates
by Zacks Equity Research
Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).
bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD
by Zacks Equity Research
bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.
Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?